IN2014DN00137A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00137A
IN2014DN00137A IN137DEN2014A IN2014DN00137A IN 2014DN00137 A IN2014DN00137 A IN 2014DN00137A IN 137DEN2014 A IN137DEN2014 A IN 137DEN2014A IN 2014DN00137 A IN2014DN00137 A IN 2014DN00137A
Authority
IN
India
Prior art keywords
useful
intermediates
preparation
present processes
processes
Prior art date
Application number
Inventor
Roland E Dolle
Bourdonnec Bertrand Le
Pierre Martin
Christian Steffen Moessner
Felix Herbert Spindler
Dirk Jost Spielvogel
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of IN2014DN00137A publication Critical patent/IN2014DN00137A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Abstract

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful for example as antagonists to the mu kappa and delta opioid receptors and thereby may be useful in the treatment of gastrointestinal motility disorders and in preventing peripheral opiate induced side effects. The present processes may offer improved yields chemical or stereochemical purity ease of preparation and/or isolation of intermediates and final product and more industrially useful reaction conditions and workability.
IN137DEN2014 2011-07-18 2012-07-17 IN2014DN00137A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161508817P 2011-07-18 2011-07-18
PCT/US2012/047082 WO2013012871A1 (en) 2011-07-18 2012-07-17 Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Publications (1)

Publication Number Publication Date
IN2014DN00137A true IN2014DN00137A (en) 2015-05-22

Family

ID=47558430

Family Applications (1)

Application Number Title Priority Date Filing Date
IN137DEN2014 IN2014DN00137A (en) 2011-07-18 2012-07-17

Country Status (9)

Country Link
US (1) US20150045556A1 (en)
EP (1) EP2734041A4 (en)
CN (1) CN103917096A (en)
AU (1) AU2012284127A1 (en)
CA (1) CA2842183A1 (en)
HK (1) HK1199794A1 (en)
IL (1) IL230506A0 (en)
IN (1) IN2014DN00137A (en)
WO (1) WO2013012871A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103804431A (en) * 2014-02-25 2014-05-21 中国人民解放军第四军医大学 Chiral ferrocene diphosphine ligand and preparation method thereof
EP3421455B1 (en) * 2017-06-29 2019-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib
CN111051280B (en) 2017-08-02 2023-12-22 弗特克斯药品有限公司 Process for preparing pyrrolidine compounds
MX2020005753A (en) 2017-12-08 2020-08-20 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5536858A (en) * 1994-02-12 1996-07-16 Hoffmann-La Roche Inc. Tetrasulfonated diphosphine compounds and metal complexes thereof for asymmetric catalytic reactions
US5553858A (en) * 1995-06-28 1996-09-10 Mckoon; Carl T. Golf putter
US6057456A (en) * 1997-10-16 2000-05-02 Yale University Transition metal-catalyzed process for preparing alpha-arylated carbonyl-containing compounds
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
CA2743978C (en) * 2008-12-18 2014-02-11 Kieran Durkin Process for synthesis of amino-methyl tetraline derivatives

Also Published As

Publication number Publication date
EP2734041A1 (en) 2014-05-28
EP2734041A4 (en) 2015-03-25
AU2012284127A1 (en) 2013-05-02
WO2013012871A1 (en) 2013-01-24
US20150045556A1 (en) 2015-02-12
CN103917096A (en) 2014-07-09
HK1199794A1 (en) 2015-07-24
IL230506A0 (en) 2014-03-31
CA2842183A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
EP2590649A4 (en) Process for the synthesis of substituted morphinans
MY175272A (en) Novel benzimidazole derivatives as ep4 antagonists
MX350211B (en) Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy )-acetimidic acid ethyl ester.
TN2012000506A1 (en) Process for the preparation of pleuromutilins
EP2755955A4 (en) Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
HUE037511T2 (en) Process for the preparation of tuluenediamine by hydrogenation of dinitrotoluene
EP2632879A4 (en) Process for the production of purified xylene isomers
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2004014310A3 (en) Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
MX2014014138A (en) New process for the preparation of 2-cyclopentyl-6-methoxy-isonic otinic acid.
IN2014DN00137A (en)
WO2010004578A3 (en) Novel and improved processes for the preparation of paliperidone
IN2015MN00013A (en)
IN2014DN00144A (en)
PL2588439T3 (en) Process for the preparation of formic acid by reacting carbondioxid wit hydrogen
MX2012002818A (en) Novel method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
WO2011004387A3 (en) Process for the preparation of dexlansoprazole polymorphic forms
WO2014087208A3 (en) A process of preparing alcaftadine
MX2014004688A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids.
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
WO2012052939A3 (en) Preparation of bicyclo[2.2.2]octan-2-one compounds
MX2013004425A (en) Diastereoselective preparation of bicyclo[2.2.2]octan-2-one compounds.
MX345168B (en) Process for preparing ranitidine hydrochloride form 2.